About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Contact
Menu
India
USA
UK
South Africa
Australia
Philippines
Germany
Netherlands
Mexico
Brazil
Canada
Switzerland
Close
About Us
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Compliance, Ethics and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
Our Business
Overview
Global Generics
Emerging Markets
India
Specialty and Innovation
Biosimilars
Our Adjacencies
Investors
Overview
Financial Reporting
Financial Information
Quarterly Results
Integrated Report
Financial Statements of Subsidiaries
Corporate Governance
Our Leadership
Committees of the Board
Code of Conduct
Policies
MOA and AOA
Shareholder Information
Stock Exchange Intimations
AGM, Postal Ballot, and EGM
Shareholding Pattern
Share Price
Ratings
Dividend
Unclaimed Dividend and Shares
Employee Stock Option Schemes
Important Communication for Shareholders
Investor FAQs
Investor Contacts
News and Events
Press Releases
Presentations
Disclosure Under Regulation 46 of SEBI (LODR) Regulations, 2015
Media
Overview
Press Releases
Media Coverage
Perspectives
Media Kit
Community
Sustainability
Overview
ESG Framework
ESG Goals and Progress
Key Highlights
ESG Ratings
ESG Governance
Careers
Contact
About Us
Our Business
Investors
Media
Community
Sustainability
Careers
Contact
Overview
The Lupin Story
Our Purpose
Our Values
Our Leadership
Compliance, Ethics and Governance
Global Presence
Our Manufacturing Approach
Quality in Action
Our Science
Awards and Recognitions
+91 22 6640 2323
info@lupin.com
Shareholder
Information
Stock Exchange Intimations
AGM, Postal Ballot, and EGM
Shareholding Pattern
Share Price
Ratings
Dividend
Unclaimed Dividend and Shares
Employee Stock Option Schemes
Important Communication for Shareholders
Investor FAQs
Investor Contacts
Stock Exchange Intimations
FY2026-27
FY2025-26
FY2024-25
FY2023-24
FY2022-23
FY2021-22
Update on acquisition of VISUfarma B.V., the Netherlands
Acquisition of Multicare Pharmaceuticals Philippines, Inc
Press Release- Completion of Acquisition of VISUfarma
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 Q4_FY26
Press Release-Earned Great Place To Work® Certification for 2026-27
Press Release- Approval of Dapagliflozin Tablets in the U.S
Press Release- Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the U.S
Grant of Stock Options under ESOP Schemes
Press Release- Launches of Dapagliflozin Tablets in the U.S
Settlement Agreement with Humana Inc
1
2
3
Next
Subscribe for
Investor Updates
Submit
I agree and accept the
Privacy Policy
and the
Terms of Use
of this website
Product Finder